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Abstract
Objectives: Fluid therapy is required to maintain
perfusion to donor organs. Recent reviews on the
choices of fluids have emphasized the safety of using
crystalloids, as opposed to fluid therapy with colloids,
which has been reported to be either unequivocally or
potentially harmful in a number of studies on various
patient populations. We aimed to analyze whether the
type of fluid administered to donors is connected with
kidney transplant outcomes.
Materials and Methods:A total of 100 consecutive brain-
dead multiorgan donors and their respective 181
kidney recipients were studied retrospectively. Data
concerning donor fluid therapy, the charac teristics of
the donors and the recipients, and outcomes after
kidney transplant were extracted from organ retrieval
and patient records. Cases with early graft function
were compared with cases with delayed graft function.
Results: Donors had received both crystalloids and
colloids in most cases (84%). Fluid therapy with
crystalloids alone was more common among the 40
recipients with delayed (30%) than in the 103
recipients with early graft function (11%) (P = .005).
Donor age, time on renal replacement therapy before
transplant, and donor fluid therapy with crystalloids
alone were independent risk factors for delayed graft
function in multivariate analysis.
Conclusions: Our results suggest that donor fluid
therapy including colloids could be beneficial instead
of harmful compared with treatment with crystalloids
alone. This finding needs to be evaluated in pro -
spective studies.
Key words: Delayed graft function, Fluid therapy, Renal
transplant
Introduction
Every year, about 170 kidney transplant procedures
are performed in Finland, with recipients most
commonly requiring transplant because of glomer -
ulonephritis, cystic kidney disease, and type 1
diabetes mellitus.1 In total, over 6000 kidney
transplants have been performed at the Helsinki
University Hospital, with 95% of donated organs
originating from brain-dead donors. Brain death is
most commonly a result of head injury, subarachnoid
or cerebral hemorrhage, an anoxic event, or cardiac
arrest.2,3 Kidney transplant procedures in Finland are
centralized to one center in Helsinki, and 90% of
donors are brain-dead donors. The 5-year kidney
graft survival rate in Finland is over 95%, and this
rate is the highest among countries in both the
European Dialysis and Transplantation Association
and Scandiatransplant registries. The kidney graft
survival rate in Finland corresponds to graft survival
of kidneys from healthy donors. Studies show that
factors affecting graft survival and early graft function
(EGF) are donor and recipient age, sex, duration of
pretransplant dialysis, mode of renal replacement
therapy (RRT), primary renal disease, acute rejection,
and postoperative creatinine values at 3, 6, and 12
months.4-7 Cold ischemia time was previously thought
to have a significant effect on kidney survival;
however, this is a debatable matter.8
A brain-dead donor is often polyuric, hypo -
tensive, and hypernatremic.9 To make up for these
deficits, intravenous fluid has to be administered;
fluid options include mainly crystalloids and
colloids.10 Of crystalloids, NaCl (0.45%-0.9%) and
Ringer acetate are widely used, whereas the most
used colloids are hydroxyethyl starch (HES), gelatin,
and albumin solutions.
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Several previous studies have shown that plasma
volume expanders have a role in causing damage to
kidneys,11-13 although these studies did not focus on
kidney transplantation. Many of these investigations
were also focused on HES. In 1993, Legendre and
associates reported on the role of HES in causing
osmotic nephrosis-like lesions in kidney transplant
but could not define HES as the reason for the
lesions.14 This resulted in a study by Cittanova and
associates, who investigated differences in effects on
kidney function of administration of gelatin only or
HES plus gelatin to brain-dead donors. They found
that HES as a plasma volume expander impaired
renal function in kidney transplant recipients.11
These initial studies were followed by further
investigations of HES-induced renal damage. It is
now known that HES has the potential of causing
tubular lesions in the form of osmotic nephrosis.12
Albumin is an expensive colloid, and its price limits
the use of it in Finland.
The aim of this study was to investigate whether
there is a correlation between the use of colloids and
EGF. Early graft function and delayed graft function
(DGF) were chosen as suitable measures of kidney
function in our study, as DGF is associated with a
poorer 1-year estimate in glomerular filtration rate.15
Materials and Methods
Study design
This retrospective study included 100 consecutive
brain-dead multiorgan donors and the corres -
ponding kidney grafts transplanted at the Helsinki
University Hospital from July 2005 to March 2013
(Figure 1). In one of the 183 transplant cases, we were
unable to find whether the patient had received 
RRT within the first week after transplant. In 
another case, the patient (a 9-kg infant with
polycystic kidney disease) died within a few hours
after transplant. Because graft function could not be
evaluated in these 2 cases, the final study population
consisted of 181 kidney transplant procedures. The
study plan was approved by the Department of
Surgery, Helsinki University Hospital Ethics
Committee.
Donors
Donors selected for this study had donated multiple
organs (ie, at least their heart and/or lungs in
addition to kidneys). Because Finland is a member of
Scandiatransplant, the donors were allowed to
originate from Finland, Denmark, Iceland, Norway,
and Sweden. All donors were brain dead as stated by
a neurologist and/or anesthesiologist. Information
about donors was gathered from ambulance forms
and data recorded before transplant at the hospital.
The total perioperative use of crystalloids and
colloids (HES, gelatin, and 4% and 20% albumin
solutions) was also recorded.
The national guidelines in Finland state that, after
a donor candidate is stated to be brain dead, the
donor needs to be treated in an intensive care unit.
The focus of the treatment is on maintaining viability
of all organs that are to be donated, and perfusion
and sufficient oxygen supply are of specific impor-
tance. Targeted mean arterial pressure is 60-90 mm
Hg, central venous pressure is 4-8 mm Hg, and 
pulse is 60-110 beats/min. Target diuresis is between
1 and 3 mL/kg/h, and polyuria is controlled with
desmopressin. Hypovolemia is corrected with Ringer
acetate, hypotonic saline solution, and 4% albumin,
and hypotension is corrected with noradrenaline or
vasopressin. If the use of Ringer acetate results in
hypernatremia, the appropriate fluid for correction
is 0.45% NaCl solution. Dopamine is used when an
inotrope is needed. Hemodynamic measurements
are monitored continuously, and laboratory tests are
conducted every 4 hours. The goal is normoglycemia
and avoidance of acidosis.16
recipients
Information about recipients was obtained from both
hand-written and electronic documents recorded
before and during surgery and in the intensive care
unit after surgery. Main parameters investigated
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Figure 1. Flow Chart for the Inclusion of Cases in the Study
Abbreviations: EGF, early graft function
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among recipients preoperatively were age, renal
illness, time on dialysis before transplant, mode of
dialysis, and long-term diagnoses. Postoperative
need for RRT and possible rejection reactions were
registered. To determine the timing that the trans -
planted kidney started functioning, statements from
surgeons regarding urine output and need for RRT
were recorded. Delayed graft function was defined
as the need for RRT within the first postoperative
week,15 and EGF was defined as successful kidney
function without RRT within the first week.
Statistical analyses
All continuous-type and ordinal variables are
presented as median (interquartile range), and
comparisons were made using the Mann-Whitney 
U test. Proportions are expressed as number
(percentage), with comparisons made with the chi-
square test or the Fisher exact test, as appropriate.
Multivariate logistic regression analysis was used to
examine the relations between graft function (EGF vs
DGF) and the risk factors identified with a univariate
significance level of < .05 (Tables 1 and 2). Factors
taken into account in the regression analysis were
donor age, donor sex, time of cold ischemia, recipient
age, recipient body mass index, recipient having or 
not having type 1 or 2 diabetes mellitus, hemo -
dialysis as the mode of RRT, time on RRT before
transplant, and donor fluid therapy with crystalloids
only. All analyses were performed with SPSS for
Windows 19.0 software (SPSS Inc., Chicago, IL,
USA). P < .05 was considered statistically significant.
All statistical tests were 2-tailed.
Results
The baseline characteristics of the 181 kidney grafts
and their recipients are shown in Table 1. Records on
fluid therapy of donors were available from 143 of
the 181 (80%) kidney transplants studied. In most
cases, donors had received both crystalloids and
colloids (120/143; 84%). Fluid therapy with
crystalloids only was associated with DGF (P = .005)
(Table 2). The donors received on average 4383 mL
(2359-6842 mL) of crystalloids preoperatively. There
was an inverse relation between use of crystalloids
and incidence of RRT. Gelatin was the most
frequently used colloid, received by the donor in
97/143 of the kidney grafts (68%).
Postoperatively, 128 of the 181 kidney grafts 
(71%) showed EGF and 53/181 (29%) showed DGF
(Figure 2). The following donor and recipient
characteristics associated with DGF in univariate
analysis (Tables 1 and 2) were studied with
multivariate logistic regression analysis: donor age,
recipient age, hemodialysis as the mode of RRT, time
on RRT before transplant, and donor fluid therapy
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table 1. Baseline Characteristics of the Deceased-Donor Kidney Grafts and
Their Recipients (N = 181)
Early Graft Function Delayed Graft  P
(n = 128) Function Value
or Nonfunction 
(n = 53)
Donor age, y 41 [26-48] (14-57) 47 [39-53] (18-61) < .001
Donor sex, No. of males 90 (70%) 41 (77%) .335
Cold-ischemia time, h 20 [18-24] (8-34) 21 [18-24] (13-32) .851
Recipient age, y 46 [33-55] (1-68) 52 [39-60] (21-75) < .001
Recipient body mass 
index, kg/m2 24 [22-27] (9-32) 24 [22-29] (19-35) .311
Recipients with 
diabetes (%) 44 (35%) 13 (25%) .184
Mode of dialysis, 
hemodialysis (%) 71 (57%) 43 (81%) .002
Time on dialysis before 
transplant, y 2 [1-3] (1-12) 3 [2-5] (1-11) .001
Data are presented as median [interquartile range] (range) or as number (%).
Comparisons between cases with early graft function and delayed graft
function were made with Mann-Whitney U test and chi-square test, as
appropriate. P < .05 was considered statistically significant.
Records on the donor fluid therapy were available from 143 of the 181
kidney transplants studied (80%). The data are presented number (%).
Comparisons between cases with early and delayed graft function 
were made with chi-square test. P < .05 was considered statistically
significant.
table 2. Type of Fluids Used in Treating Donors 
Early Graft  Delayed Graft P Value
Function Function or 
(n =103) Nonfunction
Crystalloids only 11 (11%) 12 (30%) .005
Colloids in addition to 
crystalloids 92 (89%) 28 (70%)
• Albumin 18 (18%) 7 (18%) .997
• Hydroxyethyl starch 20 (20%) 4 (10%) .176
• Gelatin 75 (73%) 22 (55%) .041
Figure 2. Diagram Showing the Outcomes of Early and Delayed Graft
Function Depending on Which Fluids Were Used in Treating the Donor
Abbreviations: DGF, delayed graft function; EGF, early graft function, HES,
hydroxyethyl starch
with crystalloids only. The best model for DGF
contained 3 independent risk factors: time on 
RRT before transplant (P = .001; OR of 1.396; 95% 
CI, 1.148-1.696), donor age (P = .015; OR of 1.048; 95%
CI, 1.009-1.089), and donor fluid therapy with
crystalloids only (P = .034, OR of 2.952; 95% CI, 
1.086-8.024), where OR is odds ratio and CI is
confidence interval.
Discussion
In this study, we found that the administration of
colloids does not worsen outcomes after kidney
transplant; rather, the effect is positive. Administration
of only crystalloids resulted in a higher incidence of
DGF than EGF. When a colloid is added to the
treatment, the result is a higher incidence of EGF
than DGF. A greater amount of crystalloids results in
less frequent use of RRT. The possible explanation of
this finding can be that crystalloids increase
circulating volume17 and perfusion, thus preventing
renal damage.
Donor age, donor fluid therapy with crystalloids
only, and recipient time on RRT before transplant
have earlier been proven to affect DGF.18 Higher age
has been proven to be a risk factor for renal failure in
patients undergoing surgery,19 partly because tissue
perfusion decreases with age.20 Because crystalloids
have been the main type of fluid used for a long time,
it is natural that there is proof of them having a great
effect on kidney function. However, our study is the
first to show that the use of crystalloids compared
with the use of colloids leads to greater incidence of
DGF rather than EGF. A longer time on RRT
preoperatively increases risk of heart disease (left
ventricular hypertrophy and cardiomegaly) as well
as postoperative infections.21 For heart disease
especially, there is a potential of worsening tissue
perfusion, thus damaging the kidneys. In our study,
cold ischemia time did not have a significant effect
on predicting DGF.
Previous studies have not been able to precisely
define how long the cold ischemia time needs to be to
cause significant kidney damage, although it has
been shown that a long cold ischemia time predicts a
worse outcome.22 There are studies claiming that,
after a cold ischemia time of 36 hours, outcomes after
kidney transplant significantly worsen, whereas other
studies claim that the cold ischemia time is of no great
significance.22,23 The mean cold ischemia time in our
study was significantly lower than 36 hours, which
could explain why it did not affect DGF. 
The reason our study clearly shows that colloids
have a positive effect on kidney grafts can be found
by looking at the use of individual colloids. It has
previously been shown that gelatin does not 
impair kidney function compared with for example
HES,24 specifically with first- and second-generation
solutions.11 This is supported by gelatin being the
colloid that was most frequently used in our study.
Other studies have shown that gelatin does not have
a significant role in kidney damage occurrence in
septic elderly patients.25 However, studies have
reported gelatin to elevate postoperative creatinine
levels26 compared with crystalloids, indicating renal
damage. This has also been demonstrated in studies
where kidney function after liver transplant was
studied with living donors.27 The effect of gelatin on
kidney function in septic patients has been compared
with the effect of crystalloids, and the conclusion has
been that using gelatin results more frequently in
acute kidney injury.28 Thus, it is difficult to generalize
the effects of gelatin on kidneys.
Previous studies have shown HES to impair renal
function.10,11-14,26,29 However, this was not supported
by our study. During 2003 to 2013, HES solutions
used at Helsinki University Hospital were all third-
generation solutions compared with the first- and
second-generation solutions used in earlier
studies.11,13,14,30-32 There has been a significant
decrease in molecular weight in newer-generation
solutions, resulting in a greater clearance and faster
excretion25 and thus resulting in less pinocytosis of
osmotic solutes and colloid-induced acute kidney
injury.12 Albumin is generally used in much smaller
amounts than other colloids.24 However, the
Albumin Italian Outcome Study has demonstrated
that albumin does not impair kidney function
compared with crystalloids,33 as has the Saline
Versus Albumin Fluid Evaluation Study.34 The
amounts of albumin used in our study were small
compared with HES and gelatin and thus can be
thought not to have adverse effects on kidneys.
Because brain-dead donors are polyuric, they are
at risk of dehydration. Usually, a colloid is given at
this time to maintain tissue perfusion and blood
pressure. If these are not maintained, kidneys will be
damaged. This explains why addition of a colloid
results in more frequent EGF. Previous studies have
investigated the role of colloids in causing kidney
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damage, but focus has not been on multiorgan
donors but merely on kidneys in general or on
patients being treated at intensive care units for other
reasons. Thus, our results are of clinical significance
as the research objective differs from previous
studies, which have mainly been focused on HES,
and other colloids have not drawn much attention.
More than 20 years ago, Cittanova and colleagues
and Legendre and associates were the first to publish
studies proving HES causes kidney damage.11,14
Since then, few studies on current colloids and their
effects on kidney function have been conducted,13
and colloids have not been frequently used during
kidney transplant procedures. Our study also
included 2 groups of patients (donors and
recipients), and we note that the care of the donor
reflects on the outcome of the recipient. The follow-
up time of recipients admitted to our study was 1
year, which is longer compared with follow-up
periods in previous studies.11,33
Many kidney transplants originate from brain-
dead donors; the results of our study are useful in
assessing fluid therapy in many kidney transplant
cases. We also used a larger patient group than
previous studies,11,14 thus increasing the credibility
of our results. All transplant procedures were done at
the same medical center; because kidney transplant
procedures have been performed at Helsinki
University Hospital since 1964, they were also made
with a great amount of experience. All relevant
information regarding patients was easily available
because of the centralization of transplant procedures
in Helsinki. Although the data were collected over a
relatively long period of time, no large changes to the
principles of fluid therapy have occurred during this
time, adding to the consistency of our material. The
fluids used in treating the donors are fluids that are
widely used in hospitals to date, making our study
current and increasing its potential usefulness. If
more studies of similar topics were made, it would
potentially increase the few available alternatives for
fluid resuscitation. The limitations of this study were
the use of computer systems and forms used in
recording the individual data from different donors.
The study was retrospective, and information was
gathered from many different sources. For some of
the donors, the information about preoperative use
of colloids and crystalloids was hand written on a
variety of documents. Because kidneys were
removed at a variety of hospitals, there were some
variations in the documentation of patient records.
This made the interpretation of notes challenging.
Donors admitted to our study were multiorgan
donors; therefore, the results are not applicable to all
cases of kidney transplant.
Because our study is the first of its kind regarding
research objectives with current fluids, it is not
enough to set new regulations concerning fluids used
in treating brain-dead kidney donors. For this, further
prospective studies are needed. Studies should also
focus on the quantitative effects of newer colloids on
kidney function. More studies with inclusion of whole
populations of kidney donors should also be done to
understand the effects of fluid therapy on kidney graft
function. In conclusion, our study shows that the
combination of colloids and crystalloids in multiorgan
donor fluid therapy predicts EGF rather than DGF, but
prospective studies focusing on newer generation
colloids should be done.
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